Impact of pre-existing MSP142-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Bergmann Leitner, Elke S ^a   Duncan, Elizabeth H ^a   Mease, Ryan M ^a   Angov, Evelina ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Clonal imprinting; Erythrocytic stage; Merozoite surface protein 1; Plasmodium; Pre existing immunity; Vaccine

Indexed keywords

MALARIA VACCINE; RECOMBINANR PLASMODIUM FALCIPARUM MSP1 VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MALARIA CONTROL; MALARIA FALCIPARUM; MOUSE; NONHUMAN; SEROLOGY;

ANIMALS; ANTIBODIES, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; IMMUNOGLOBULIN G; MALARIA; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84865820030     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-315     Document Type: Article

References (56)

1. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P, J Exp Med 1990 172 1633 1641 10.1084/jem.172.6.1633 2258697
2. Passive immunity in Plasmodium knowlesi malaria. Butcher GA, Cohen S, Garnham PC, Trans R Soc Trop Med Hyg 1970 64 850 856 10.1016/0035-9203(70)90104- 5 4993013
3. Gamma-globulin and acquired immunity to human malaria. Cohen S, Mc Gregor IA, Carrington S, Nature 1961 192 733 737 10.1038/192733a0 13880318
4. Merozoite surface protein-1 epitopes recognized by antibodies that inhibit Plasmodium falciparum merozoite dispersal. Lyon JA, Carter JM, Thomas AW, Chulay JD, Mol Biochem Parasitol 1997 90 223 234 10.1016/S0166-6851(97) 00155-2 9497045
5. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL, Bloland PB, Kaslow DC, Lal AA, AmJTrop Med Hyg 1998 58 211 219
6. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM, J Infect Dis 1996 173 765 769 10.1093/infdis/173.3.765 8627050
7. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of the merozoite surface protein-1 (MSP-119) can play a protective role against Blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. John CC, ODonnell RA, Sumba PO, Moormann AM, Koning-Ward TF, King CL, Kazura JW, Crabb BS, J Immunol 2004 173 666 672 15210830
8. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA, J Exp Med 1994 180 389 393 10.1084/jem.180.1.389 7516416
9. Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and 2 of Plasmodium falciparum. Gerold P, Schofield L, Blackman MJ, Holder AA, Schwartz RT, Mol Biochem Parasitol 1996 75 131 143 10.1016/0166-6851(95)02518-9 8992312
10. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. Morgan WD, Birdsall B, Frenkiel TA, Gradwell MG, Burghaus P, Syed SE, Uthaipibull C, Holder AA, Feeney J, J Mol Biol 1999 289 113 122 10.1006/jmbi.1999.2753 10339410
11. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA, Infect Immun 2005 73 287 297 10.1128/IAI.73.1.287-297.2005 15618165
12. Immunity to erythrocytes stages of malarial parasites. Long CA, Daly TM, Kima P, Srivastava I, AmJTrop Med Hyg 1994 50 27 32
13. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW, PLoS One 2008 3 2830 10.1371/journal.pone.0002830 18665258
14. Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum. Arnot DE, Cavanagh DR, Remarque EJ, Creasey AM, Sowa MP, Morgan WD, Holder AA, Longacre S, Thomas AW, Clin Vaccine Immunol 2008 15 1345 1355 10.1128/CVI.00172-08 18550731
15. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. Reed ZH, Kieny MP, Engers H, Friede M, Chang S, Longacre S, Malhotra P, Pan W, Long C, Vaccine 2009 27 1651 1660 10.1016/j.vaccine.2008. 10.093 19038302
16. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC, Mol Med 1995 1 325 332 8529111
17. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH, Infect Immun 2001 69 1536 1546 10.1128/IAI.69.3.1536-1546.2001 11179324
18. Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. Lee EAM, Flanagan KL, Minigo G, Reece WHH, Bailey R, Pinder M, Hill AVS, Plebanski M, Eur J Immunol 2006 36 1168 1178 10.1002/eji.200526010 16619284
19. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, Long CA, Angov E, Lyon JA, AmJTrop Med Hyg 2006 75 437 442
20. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. Thera MA, Doumbo OK, Coulibaly B, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV, Plos Clin Trials 2006 1 34 10.1371/journal.pctr.0010034 17124530
21. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. Withers MR, McKinney D, Ogutu BR, Waitumbi J, Milman JB, Apollo OJ, Allen OG, Tucker K, Soisson L, Diggs C, Leach A, Wittes J, Dubovsky F, Stewart VA, Remich SA, Cohen J, Ballou WR, Holland C, Lyon JA, Angov E, Stoute JA, Martin SK, Heppner DG, PLoS Clin Trials 2006 1 32 10.1371/journal.pctr.0010032 17124529
22. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with ASO2A in adults in western Kenya. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman JB, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse C, Holland C, Diggs C, Wittes J, Heppner DG, Vaccine 2007 25 176 184 10.1016/j.vaccine.2005. 11.037 16388879
23. Phase I safety and immunogenicity trial of FMP1/ASO2A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Ockenhouse C, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart VA, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG, Vaccine 2006 24 3009 3017 10.1016/j.vaccine.2005.11.028 16356603
24. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi J, Diggs C, Wittes J, Malkin E, Leach A, Soisson L, Milman JB, Otieno L, Holland C, Polhemus M, Remich SA, Ockenhouse C, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR, PLoS One 2009 4 4708 10.1371/journal.pone.0004708 19262754
25. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Miller LH, Roberts T, Shahbuddin M, McCutchan TF, Mol Biochem Parasitol 1993 59 1 14 10.1016/0166-6851(93)90002-F 8515771
26. Allelic dimorphism in a sufrace antigen gene of the malaria parasite Plasmodium falciparum. Tanabe K, Mackay M, Goman M, Scaife JG, Mol Biol Evol 1987 9 381 393
27. Protective immune reponses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not the adjacent 33-kDa region. Ahlborg N, Ling IT, Howard W, Holder AA, Riley EM, Infect Immun 2002 70 820 825 10.1128/IAI.70.2.820-825.2002 11796616
28. Fine specificity of neonatal lymphocytes to an abundant malaria blood-stage antigen: epitope mapping of Plasmodium falciparum MSP1(33). Malhotra I, Wamachi AN, Mungai PL, Mzungu E, Koech D, Muchiri E, Moormann AM, King CL, J Immunol 2008 180 3383 3390 18292564
29. T cell epitope regions of the P.falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines. Pusic KM, Hashimoto CN, Lehrer A, Aniya C, Clements DE, Hui GS, PLoS One 2011 6 24782 10.1371/journal.pone.0024782 21931852
30. Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria. Spring MD, Chelimo K, Tisch DJ, Sumba PO, Rochford R, Long CA, Kazura JW, Moormann AM, Infect Immun 2010 78 4431 4441 10.1128/IAI.00415-10 20696832
31. Epidemiologv and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. Davenport FM, Hennessy AV, Francis T, J Exp Med 1953 98 641 656 10.1084/jem.98.6.641 13109114
32. Dengue conundrums. Gibbons RV, Int J Antimicrob Agents 2010 36 36 S39 20696556
33. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Seregin SS, Amalfitano A, Expert Opin Biol Ther 2009 9 1521 1531 10.1517/14712590903307388 19780714
34. Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA, Mol Biochem Parasitol 2003 128 195 204 10.1016/S0166-6851(03)00077-X 12742586
35. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. Qari SH, Shi YP, Goldman IF, Nahlen BL, Tibayrenc M, Lal AA, Mol Biochem Parasitol 1998 92 241 252 10.1016/S0166-6851(98)00010-3 9657329
36. Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. Angov E, Hillier CJ, Kincaid RL, Lyon JA, PLoS One 2008 3 2189 10.1371/journal.pone. 0002189 18478103
37. Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice. Khan F, Legler PM, Mease RM, Duncan EH, Bergmann-Leitner E, Angov E, Biotechnol J 2012 7 133 147 10.1002/biot.201100331 22076863
38. Improved technique for the preparation of water-in-oil emulsions containing protein antigens. Vulliet R, Biotechniques 1996 20 797 800 8723921
39. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E, Tsokos GC, Vaccine 2007 25 7732 7736 10.1016/j.vaccine.2007.08.030 17931754
40. Automated synchronization of Plasmodium falciparum parasites by culture in a temperature-cycling incubator. Haynes JD, Moch JK, Methods Mol Med 2002 72 489 497 12125145
41. Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies. Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J, Angov E, Malar J 2008 7 129 10.1186/1475-2875-7- 129
42. Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trials. Bergmann-Leitner ES, Duncan EH, Burge JR, Spring M, Angov E, AmJTrop Med Hyg 2008 78 468 471
43. MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum. Bergmann-Leitner ES, Duncan EH, Angov E, Malar J 2009 8 183 10.1186/1475-2875-8-183
44. Regulation of interleukin-12 signalling during T helper phenotype development. Jacobson NG, Szabo SJ, Guler ML, Gorham JD, Murphy KM, Adv Exp Med Biol 1996 409 61 73 10.1007/978-1-4615-5855-2-9 9095224
45. Progress in the development of recombinant and synthetic blood-stage vaccines. Mahanty S, Saul A, Miller LH, J Exp Biol 2003 206 3781 3788 10.1242/jeb.00646 14506213
46. Malaria Parasites. Bergmann-Leitner E, Duncan EH, Angov E, Malaria Parasites Intech-Open Access Publisher, Croatia, Rijeka OO, 2012
47. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov E, Moormann AM, Kazura JW, PLoS One 2008 3 3557 10.1371/journal.pone.0003557 18958285
48. Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized. Miura K, Zhou H, Diouf A, Tullo G, Moretz SE, Aebig JA, Fay MP, Miller LH, Doumbo OK, Sagara I, Dicko A, Long CA, Ellis RD, Vaccine 2011 29 2255 2261 10.1016/j.vaccine.2011.01. 043 21277408
49. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. Miura K, Zhou H, Moretz SE, Diouf A, Thera MA, Dolo A, Doumbo OK, Malkin E, Diemert DJ, Miller LH, Mullen GE, Long C, J Immunol 2008 181 8776 8783 19050299
50. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1.adjuvanted with ASO2A, in malaria naive adults at the Walter Reed Army Institute of Research. Polhemus M, Magill AJ, Cummings JF, Kester KE, Ockenhouse C, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs C, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG, Vaccine 2007 25 4203 4212 10.1016/j.vaccine.2007.03.012 17442466
51. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusu A, Dubois MC, Cohen J, Nixon JN, et al. PLoS One 2008 3 1465 10.1371/journal.pone.0001465 18213374
52. Lack of allele-specific efficacy of a bivalent AMA1-malaria vaccine. Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, Dicko A, Niangaly A, Duan J, Ellis RD, Miller LH, Su X-Z, Plowe CV, Doumbo OK, Malar J 2010 9 175 10.1186/1475-2875-9-175
53. A field trial to assess a blood-stage malaria vaccine. Thera MA, Doumbo OK, Coulibaly B, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra A, Daou M, Dolo A, Tolo Y, Sissoko M, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV, N Engl J Med 2011 365 1004 1013 10.1056/NEJMoa1008115 21916638
54. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. Daly TM, Long CA, J Immunol 1995 155 236 243 7602100
55. Characterization of human T- and B-cell epitopes in the C-terminus of Plasmodium falciparum merozoite surface protein 1: evidence of poor T-cell recognitiion of polypeptides with numerous disulfide bonds. Egan A, Waterfall M, Pinder M, Holder AA, Riley EM, Infect Immun 1997 65 3024 3031 9234749
56. A recombinant blood-stage malaria vaccine reduces Plasmodium density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP, J Infect Dis 2002 185 820 827 10.1086/339342 11920300